- Previous Close
4.1200 - Open
4.1600 - Bid 4.0500 x 100
- Ask 4.0400 x 100
- Day's Range
3.9800 - 4.1650 - 52 Week Range
2.1400 - 4.9500 - Volume
75,699 - Avg. Volume
51,843 - Market Cap (intraday)
171.47M - Beta (5Y Monthly) 1.46
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5100 - Earnings Date Nov 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.00
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
www.diamedica.comRecent News: DMAC
View More
Performance Overview: DMAC
Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DMAC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DMAC
View MoreValuation Measures
Market Cap
171.42M
Enterprise Value
117.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.21
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.54%
Return on Equity (ttm)
-35.18%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-19.9M
Diluted EPS (ttm)
-0.5100
Balance Sheet and Cash Flow
Total Cash (mrq)
54.05M
Total Debt/Equity (mrq)
0.73%
Levered Free Cash Flow (ttm)
-11.14M
Research Analysis: DMAC
View MoreCompany Insights: DMAC
DMAC does not have Company Insights